Terms: = Ovarian germ cell tumor AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
31 results:
1. brca1/2 reversion mutations in a pan-cancer cohort.
Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
[TBL] [Abstract] [Full Text] [Related]
2. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract] [Full Text] [Related]
3. Exceptional Response of Pancreatic Acinar cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a germline BRCA2 Variant.
Sunami T; Yamada A; Kondo T; Kanai M; Nagai K; Uchida Y; Yokode M; Matsumori T; Uza N; Murakami H; Yamada T; Muto M
Pancreas; 2022 Oct; 51(9):1258-1262. PubMed ID: 37078954
[TBL] [Abstract] [Full Text] [Related]
4. The BRCAness Landscape of Cancer.
Guo M; Wang SM
Cells; 2022 Dec; 11(23):. PubMed ID: 36497135
[TBL] [Abstract] [Full Text] [Related]
5. Identification and Management of Pathogenic Variants in brca1, BRCA2, and PALB2 in a tumor-Only Genomic Testing Program.
Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
[TBL] [Abstract] [Full Text] [Related]
6. Predicting the Likelihood of Carrying a
Ang BH; Ho WK; Wijaya E; Kwan PY; Ng PS; Yoon SY; Hasan SN; Lim JMC; Hassan T; Tai MC; Allen J; Lee A; Taib NAM; Yip CH; Hartman M; Lim SH; Tan EY; Tan BKT; Tan SM; Tan VKM; Ho PJ; Khng AJ; Dunning AM; Li J; Easton DF; Antoniou AC; Teo SH
J Clin Oncol; 2022 May; 40(14):1542-1551. PubMed ID: 35143328
[TBL] [Abstract] [Full Text] [Related]
7. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract] [Full Text] [Related]
8. Therapeutic Implications of germline Testing in Patients With Advanced Cancers.
Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
[TBL] [Abstract] [Full Text] [Related]
9. germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
Liu J; Prager-van der Smissen WJC; Collée JM; Bolla MK; Wang Q; Michailidou K; Dennis J; Ahearn TU; Aittomäki K; Ambrosone CB; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Augustinsson A; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bernstein L; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Brauch H; Brenner H; Briceno I; Brucker SY; Brüning T; Burwinkel B; Cai Q; Cai H; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Choi JY; Christiaens M; Clarke CL; ; Couch FJ; Czene K; Daly MB; Devilee P; Dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Fasching PA; Figueroa J; Flyger H; Fritschi L; Gago-Dominguez M; Gapstur SM; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Goldberg MS; Goldgar DE; Guénel P; Haiman CA; Håkansson N; Hall P; Harrington PA; Hart SN; Hartman M; Hillemanns P; Hopper JL; Hou MF; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakimovska M; Jakubowska A; John EM; Kaaks R; Kang D; Keeman R; Khusnutdinova E; Kim SW; Kraft P; Kristensen VN; Kurian AW; Le Marchand L; Li J; Lindblom A; Lophatananon A; Luben RN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mariapun S; Matsuo K; Maurer T; Mavroudis D; Meindl A; Menon U; Milne RL; Muir K; Mulligan AM; Neuhausen SL; Nevanlinna H; Offit K; Olopade OI; Olson JE; Olsson H; Orr N; Park SK; Peterlongo P; Peto J; Plaseska-Karanfilska D; Presneau N; Rack B; Rau-Murthy R; Rennert G; Rennert HS; Rhenius V; Romero A; Ruebner M; Saloustros E; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Shen CY; Shu XO; Simard J; Sohn C; Southey MC; Spinelli JJ; Tamimi RM; Tapper WJ; Teo SH; Terry MB; Torres D; Truong T; Untch M; Vachon CM; van Asperen CJ; Wolk A; Yamaji T; Zheng W; Ziogas A; Ziv E; Torres-Mejía G; Dörk T; Swerdlow AJ; Hamann U; Schmidt MK; Dunning AM; Pharoah PDP; Easton DF; Hooning MJ; Martens JWM; Hollestelle A
Sci Rep; 2020 Jun; 10(1):9688. PubMed ID: 32546843
[TBL] [Abstract] [Full Text] [Related]
10.
Santana Dos Santos E; Lallemand F; Petitalot A; Caputo SM; Rouleau E
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32481735
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of brca1 mutation and topoisomerase II-directed therapy.
Bagal B; Kumar R; Gaur T; Talreja V; Bonda A; Patkar N; Shetty D; Kowtal P; Subramanian PG; Gupta S; Sarin R; Hasan SK
Med Oncol; 2020 Apr; 37(5):48. PubMed ID: 32277283
[TBL] [Abstract] [Full Text] [Related]
12. treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Valiakhmetova A; Gorelyshev S; Konovalov A; Trunin Y; Savateev A; Kram DE; Severson E; Hemmerich A; Edgerly C; Duncan D; Britt N; Huang RSP; Elvin J; Miller V; Ross JS; Gay L; McCorkle J; Rankin A; Erlich RL; Chudnovsky Y; Ramkissoon SH
Oncologist; 2020 Feb; 25(2):e198-e202. PubMed ID: 32043779
[TBL] [Abstract] [Full Text] [Related]
13. Routine Plasma-Based Genotyping to Comprehensively Detect germline, Somatic, and Reversion
Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
[TBL] [Abstract] [Full Text] [Related]
14. germline and Somatic tumor Testing in Epithelial ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA; Norquist B; Lacchetti C; Armstrong D; Grisham RN; Goodfellow PJ; Kohn EC; Levine DA; Liu JF; Lu KH; Sparacio D; Annunziata CM
J Clin Oncol; 2020 Apr; 38(11):1222-1245. PubMed ID: 31986064
[TBL] [Abstract] [Full Text] [Related]
15. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline
Snow A; Ricker C; In GK
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31227566
[TBL] [Abstract] [Full Text] [Related]
16. Distinct DNA Methylation Profiles in ovarian tumors: Opportunities for Novel Biomarkers.
Losi L; Fonda S; Saponaro S; Chelbi ST; Lancellotti C; Gozzi G; Alberti L; Fabbiani L; Botticelli L; Benhattar J
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882921
[TBL] [Abstract] [Full Text] [Related]
17. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
Altinoz MA; Ozpinar A; Elmaci I
Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
[TBL] [Abstract] [Full Text] [Related]
18. Chemosensitivity of brca1-Mutated ovarian Cancer cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract] [Full Text] [Related]
19. Reversion of brca1/2 germline Mutations Detected in Circulating tumor DNA From Patients With High-Grade Serous ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract] [Full Text] [Related]
20. Rapid selection of brca1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in brca1 mutation carriers.
Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
[TBL] [Abstract] [Full Text] [Related]
[Next]
